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Objective: To investigate the efficacy and safety of Antiwei, a traditional Chinese prescription,
in the treatment of influenza.
Methods: In a multi-center, randomized, double-blind, placebo-controlled trial, we recruited
480 adults aged 18 to 65 years within 36 h of onset of influenza-like symptoms. There were 225
patients with confirmed influenza. Eligible patients were randomly assigned 6 g of Antiwei
(nZ 360) or placebo (nZ 120) twice daily for three days. All patients recorded their temper-
ature and symptoms on diary cards during treatment. Analyses were performed in both the
influenza-like population and the influenza-confirmed population.Group, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital,
. 37, Chengdu 610041, PR China. Tel.: þ86 28 8542 3546; fax: þ86 28 8542 3373.
@hotmail.com (G. Wang).
0 Elsevier Ltd. All rights reserved.
Chinese herbs in treatment of influenza: A randomized, double-blind, placebo-controlled trial 1363Results: Antiwei increased patients’ recovery by 17% (P < 0.001), and reduced the severity of
illness measured by the median symptom score by 50% (P < 0.001) in both the influenza-like
and the influenza-confirmed populations, compared to placebo. The influenza-confirmed
patients reported reductions in the severity of fever (P Z 0.002), cough (P Z 0.023) and
expectoration (P Z 0.004) after one-day of treatment with Antiwei, compared to placebo.
The adverse event profiles were similar for Antiwei and placebo.
Conclusion: Antiwei was effective and well tolerated in treatment of natural influenza infec-
tion in adults. Antiwei represents a clinically valuable intervention in the management of influ-
enza.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Influenza caused by infection with either influenza A or B
viruses, is one of the most common and important respi-
ratory illnesses affecting all ages. Uncomplicated influenza
is generally resolved over a 2- to 5-day period, although
cough and malaise can persist for weeks. Influenza
epidemics such as the influenza A (H1N1) pandemic in 2009,
which is the first pandemic since 1968, are associated with
increased morbidity and hospitalization rates, and excess
mortality1,2 within the most vulnerable populations,
including the elderly, infants and those with underlying
medical conditions.3
Although drugs such as the adamantanes (i.e., aman-
tadine and rimantadine) and the neuraminidase inhibitors
(i.e., oseltamivir and zanamivir) are available to treat or
prevent influenza, recent emergence of adamantane
resistant strains has rendered these agents less effec-
tive.4,5 In addition, sporadic cases of oseltamivir-resistant
influenza A (H1N1) virus infection have been reported
worldwide following the H1N1 pandemic of 2009.6 Even
though vaccination strategies against influenza A (H1N1)
virus are now present in China, some patients may look
beyond conventional treatments and consider comple-
mentary and alternative medicines, including traditional
Chinese medicine (TCM), in this situation. TCM represents
one aspect of Chinese medical philosophy that is charac-
terized by an emphasis on maintaining and restoring
balance. Chinese medicinal herbs, the most important
component of TCM, are derived from plants and usually
incorporate one or more herbs as the basic drugs to treat
the disease.7 Supplemental use of Chinese medicinal
herbs were found to be beneficial in the management of
severe acute respiratory syndrome (SARS) in 20038e10 and,
based on that supplementary treatment, Chinese medic-
inal herbs might also show promise for treating or pre-
venting influenza and influenza-like illness. Some
randomized controlled trials (RCTs) have been published,
but the evidence for treating or preventing influenza by
TCM has not yet been convincingly established, due to
poor reporting quality and small sample size.11,12
Antiwei granule is a traditional Chinese prescription,
consisting of Mahuang (Herba Ephedra), Baimaogeng (Rhi-
zoma Imperatae), Gegen(Radix puerariae), Guizhi (Ramu-
lus Cinnamoumum), Kuxingren (Semen Armeniacae
Amarum.), Ganjiang (Rhizoma Zingiberis) and Gancao
(Radix Glycyrrhizae). One gram of Antiwei granule equals
3.83 g of crude drug. The resource, pharmacological actionsand components in this formula are listed in Table 1.13
According to TCM, Mahuang and Baimaogen in this
formula, which are regarded as “the principal” herbs, could
relieve exterior disorder and defervesce. Gegen and
Guizhi, which serve as “the Minister”, cooperate with “the
principal” to relieve exterior syndrome and defervesce.
Kuxingren and Ganjiang are “the adjuvant drug”, which can
open the inhibited lung-energy, regulate the flow of Qi,
eliminate phlegm and relieve cough. Gancao serves as “the
guiding drug”, which can moisten lung to arrest cough and
coordinate all of the drug actions of this formula.
Antiwei has been used widely based on clinical experi-
ence rather than the evidence of RCTs in the treatment of
influenza-like illness (such as fever, headache, pain and
cough) in China.14 Therefore, a prospective, multi-center,
randomized, double-blind, placebo-controlled clinical trial
was undertaken to investigate the efficacy and safety of
Antiwei granule for the treatment of naturally acquired
influenza in humans.Subjects and methods
Patients and ethics
Eligible patients, who presented with fever over 37.4 C
and at least one respiratory symptom (cough, sore throat,
or nasal symptom) and at least one constitutional symptom
(headache, fatigue, myalgia, thirst or chills), were
recruited from emergency departments from January to
June, 2007. The inclusion criteria were as follows: (1)
clinical diagnosis of influenza; (2) age 18 to 65 years; (3)
within 36 h of onset of influenza-like illness; (4) written
informed consent. The exclusion criteria were as follows:
(1) any treatments after onset of influenza-like illness; (2)
other confirmed upper respiratory viral infections; (3) sus-
pected bacterial infection (based on symptoms, leukocyte
count> 10.0  109/L or neutrophil granulocyte 80%); (4)
pregnancy or breast-feeding; (5) allergies to food additives,
drugs, and any components in Antiwei granule; (6) current
alcoholism or drug abuse; (7) severe diseases of cardiac,
respiratory, hepatic, renal, central nervous system, hae-
matopoietic system cancer; (8) the inability to understand
and complete this study; (9) current psychiatric illness or
dementia; (10) clinically important chronic illnesses or
known HIV infection, receiving steroids or other immuno-
suppressants, or having been vaccinated against influenza
in the previous 12 months. We also required that patients of
childbearing age use contraception.
Table 1 Standard formula of Antiwei granule.
Chinese name Pharmaceutical name Source Pharmacological actions ditional Chinese medicine Weights
(%)
Mahuang Herba Ephdra The dried herbaceous stem of
Ephedra sinica Stapf, Ephedra
equisetina Bunge or ephedra
intermedia Schrenk et C.A. Meyer
(family Ephedraceae)
To induce seating for re g the superficies in cases of
wind-cold affliction; to asthma; to induce diuresis
for relieving edema cau wind
10.99
Bai mao gen Rhizoma Imperatae the dried rhizome of Imperate
cylindrical Beauv. Var. major
(nees) C.E. Hubb. (family Graminae)
To cool blood, arrest bl , clear heat and induce
diuresis for the treatme pistaxis and hematuria
due to blood heat, edem undice, and stranguria
associated with heat
32.68
Gegen Radix puerariae The dried root of Pueraria lobata
(Wild) Ohwi or Pueraria thomsonii
Benth. (family Leguminosae)
To reduce heat in cases erior syndrome with fever
and painful stiffness of ck and nape; to relieve
thirst in febrile diseases iabetes mellitus; to arrest
diarrhea in spleen insuf y; to promote eruption
for measles
16.48
Guizhi Ramulus
Cinnamoumum
The died Young stem of Cinnamomum
cassia Presl. (family Lauraceae)
to induce sweating for r ng the muscles in cases of
wind-cold affliction; to and unblock the meridians
to relieve various pains cold and congealing blood;
to stimulate menstrual rge for treating amenorrhea
10.99
Ganjiang
(Dried ginger)
Rhizoma Zingiberis The dried rhizome of Zingiber
officinale (Wild.) Rose. (family
Zingiberaceae)
To warm the spleen and ach for the relief of nausea,
vomiting, abdominal pa diarrhea due to deficiency-cold
of the spleen and stoma warm the lung for treating
chronic cough with thin and foamy expectoration
6.59
Ku xing ren
(Bitter Apricot
Seed)
Semen Armeniacae
Amarum.
The dried ripe seed or kernel of
Prunus armeniaca L. var ansu Maxim.,
Prunus Sibirica L., Prunus mandshurica
(Maxim.) Koehne or Prunus armeniaca
L. (family Rosaceae)
To relieve cough and dy with profuse expectoration;
to relieve constipation
10.99
Gancao
(Licorice Root)
Radix Glycyrrhizae The dried root and rhizome of
Glycyrrhiza uralensis Fisch.,
Glycyrrhiza inflata Bat. or
Glycyrrhiza glabra L. (family
Leguminosae)
To replenish qi and toni heat for treating arrhythmia
in cases of heart qi defi ; to tonify the spleen for
treating lassitude, anor d loose bowels in cases of
spleen insufficiency; to epigastric colic and
spastic pain of the limb ispel phlegm and arrest
cough; to clear heat an teract toxin for treating
sore throat, boils, sores rug overdose; most
frequently for modulati ingredients in a prescription
10.99
Data from Classified dictionary of traditional Chinese medicine by Zhu-fan Xie.13
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Chinese herbs in treatment of influenza: A randomized, double-blind, placebo-controlled trial 1365The Medical Ethics Committee of West China Hospital at
Sichuan University approved this study (No. IRB-2007-13),
and it is in accordance with the recent principles of the
Declaration of Helsinki.15 All patients gave informed
consent and were free to withdraw from the study at any
time.
Study design and interventions
This was a prospective, multiple-center, randomized,
double-blind, placebo-controlled trial, which was under-
taken at eight Chinese centers: three in North China, three
in Northeast China, one in Northwest China, and one in
West China. Patients were randomized in a double-blind
fashion to receive either Antiwei granule or placebo. The
randomization code was generated by the PRCO PLAN of
the analysis system of SAS (Version 6.12 for Windows).
Allocation details were sealed in an envelope, and were
unknown both to investigators and participants in this
study.
Antiwei and placebo were supplied by Tasly Group
(Tianjin, China), the herbal composition of Antiwei is pre-
sented in Table 1. The placebo granule was composed of
starch and bitter agents, but was visually indistinguishable
from the Antiwei in appearance, color, size and packaging.
The subjects in the Antiwei group received 6 g of Antiwei
granule twice a day for three days, whereas the patients in
the placebo group received 6 g of placebo twice a day for
three days. All patients were treated in an equivalent
fashion. We assessed compliance by daily diary cards and
review of the returned medication at the end of treatment.
Assessments
We took present, past and personal medical histories,
measured vital signs such as temperature, respiration rate,
heart rate and blood pressure, did physical examinations of
pharynx, larynx and lung in respiratory system, and
collected baseline virological samples before treatment.
After accepting treatment, patients recorded their axil-
lary’s temperature every 2 h for up to 12 h on day one. On
days 2 and 3, they recorded their axillary’s temperature at
8am, 10am, 12am, 4pm and 8pm in a diary card. To exclude
other respiratory illnesses, subjects received chest X-ray
screening before beginning treatment. The presence and
severity of influenza symptoms, including cough, sore
throat, nasal obstruction and rhinorrhoea, headache,
fatigue, myalgia, thirst and chills, were recorded once daily
using a four-point scale (0 absent, 1 mild, 2 moderate, and
3 severe). The first record was performed when the patient
was admitted, and the next two records (on days 1 and 3
after treatment) were done in the morning. Influenza was
confirmed by a direct immunofluorescent antibody assay
(DFA) of nasopharyngeal swabs, which showed sensitivities
of 89.7% for influenza A virus and 87.9% for influenza B virus
and specificities of 99.3% for influenza A virus and 100% for
influenza B virus.16 Treatment assignment was blinded
during virological testing, which was done at West China
Hospital, Sichuan University, Chengdu.
The primary endpoints were severity of illness
(measured by the mean symptom scores for the whole
treatment period) and the number of recovered patients in
the intention- to treat and influenza-confirmed pop-
ulations. Recovery was defined as absence of fever(temperature< 37.4 C) and all nine symptoms (chills,
headache and myalgia, nasal obstruction, sore throat,
fatigue, cough, rhinorrhoea, expectoration, and thirst).
Secondary outcomes included the length of time to alle-
viate fever within the first 24 h after treatment, the
severity of each symptom, and the rate of influenza-virus-
positive conversion to negative for the influenza-confirmed
population at entry.
Adverse effects record
Participants were required to record any unexpected signs,
symptoms, or feelings during the treatment period, and
routine tests of blood, urine, stool, as well as hepatic and
renal functions and electrocardiogram (ECG) were per-
formed at admission and again after treatment to assess
safety in both groups.
Statistical analysis
A sample size of 135 for the Antiwei group and 45 for the
placebo group, at a ratio of 3:1, were calculated according
to published data17 to have a power of 80% or greater to
detect a difference of 10 percent in recovery rate,
assuming a significance level of 0.05. Sample size calcula-
tions were performed using a normal approximation to the
Wilcoxon rank-sum test.
Influenza-like and influenza-confirmed populations were
both analyzed, with the influenza-like population consisting
of randomized patients who received at least one dose of
medication in this study. Safety analyses were performed
on those populations, which included all patients who
received at least one dose of medication and who had at
least one follow-up for safety, whether or not they were
withdrawn prematurely.
All analyses were performed using Stata 11.0. Measure-
ment data showing a normalized distribution were
described as mean  standard deviation and analyzed with
analysis of variance to determine the difference between
the Antiwei and placebo group. Measurement data showing
a non-normalized distribution were described as median
and analyzed by the Wilcoxon rank-sum test. Frequency
data were analyzed using the chi-squared (c2) or Fisher’s
tests. The primary endpoints were analyzed using the
survival method. KaplaneMeier curves were constructed
and significance-tested using the log-rank method. For the
mean symptom scores we used analysis of variance. The
rate of influenza-virus-positive conversion to negative was
compared between different groups with c2 test. P 0.05
for two-tailed tests was considered to be significant.
Results
Trial profile and patient characteristics
A total of 480 eligible patients were enrolled and randomly
assigned to receive Antiwei granule (nZ 360) or placebo
(nZ 120). Of these, 34 patients withdrew from the study
early for several reasons including lost to follow-up (Anti-
wei: nZ 6; Placebo: nZ 7), protocol violation (Antiwei:
nZ 15; Placebo: nZ 3), and refusal to continue (Antiwei:
nZ 1; Placebo: nZ 2). Overall, 225 (48.2%) patients had
laboratory-confirmed influenza (Fig. 1). Of these, 125
Eligible patients (n=480) 
Randomized to Antiwei (n=360) Randomized to placebo (n=120) 
Influenza-like illness (n=353) 
Influenza (n=177) 
Influenza-like illness (n=114) 
Influenza (n=48) 
Withdrawn (n=22) 
Loss of follow-up (n=6) 
Protocol violation (n=15) 
Refusal (n=1) 
Withdrawn (n=12)
Loss of follow-up (n=7) 
Protocol violation (n=3) 
Refusal (n=2) 
Figure 1 Trial profile.
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Figure 2 The number of patients recovering after three-day
treatment.
1366 L. Wang et al.(55.6%) had influenza A, 74 (32.9%) had influenza B and 26
(11.5%) had both influenza A and B (Table 2). All available
data from these patients were included in the efficacy and
safety analyses. No differences were observed between
two groups in the demographics and clinical characteristics.
Safety of the study drug was assessed for all 480 patients.
Efficacy
For influenza-confirmed patients, Antiwei resulted in
significantly more patients recovering or showing a reduc-
tion in the severity of illness. The number of patients
recovering after three days of treatment was 42 of 177
(23.2%) in the Antiwei group (PZ 0.009) (Fig. 2) compared
to 3 of 48 (6.25%) in the placebo group, and this benefit was
also seen in the patients with influenza-like disease (86/353
vs. 10/114, P< 0.001). Similarly, Antiwei resulted in
significant reductions in the total symptom score after
three days of treatment in the influenza-confirmed pop-
ulation (15.20 6.25 vs. 10.26 7.72, P< 0.001) and inTable 2 Demographic characteristics and clinical characteristic
Patients Antiwei
Population with influenza-like illness
n 353
Age (years) 37.8  12.6
Gender (Male/female) 142/211
Duration (hours) 18.4  8.1
Total symptom score (points)a 20.1  5.4
Axillary temperature (C) 38.03  0.44
Influenza-confirmed population
n 177
Influenza A, B or both A and B 99/60/18
Age (years) 37.3  12.3
Gender (Male/female) 72/105
Duration (hours) 18.8  8.3
Total symptom score (points)a 20.2  5.3
Axillary’s temperature (C) 38.05  0.44
a Total symptom scores include cough, sore throat, nasal symptoms
thirst and chills assessed by a four-point scale (0 absent, 1 mild, 2
Mean SD.the influenza-like population (15.07 6.32 vs.
8.81 6.99, P< 0.001) compared to placebo.
After one-day treatment, the improved percentage of
symptom score (difference between the symptom scores at
baseline and after one-day treatment is divided by the
symptom score at baseline) in fever (57.9% vs. 34.4%,
PZ 0.002), cough (32.9% vs. 16.3%, PZ 0.023) and expec-
toration (32.9% vs. 16.3%, PZ 0.004) was significantly
reduced in the Antiwei group compared to placebo in
influenza-confirmed patients. There was no statistically
significant reduction seen in the severity of chills (34.9% vs.
28.1%, PZ 0.307), headache and myalgia (96.6% vs. 95.8%,
PZ 0.871), nasal obstruction (26.1% vs. 36.9%, PZ 0.892),
rhinorrhea (34.5% vs. 23.4%, PZ 0.107), sore throat (25.7%
vs. 17.0%, PZ 0.088), fatigue (24.8% vs. 25.9%, PZ 0.863)
or thirst (35.3% vs. 21.5%, PZ 0.072) (Fig. 3). At the same
time, the median temperature fell by 0.8 C from baseline
in the Antiwei group but by only 0.4 C in the placebo group
(PZ 0.0001). Treatment benefit for fever was apparent ass of patients at baseline.
Placebo P
114
38.6  12.3 0.573
47/67 0.850
18.7  7.7 0.756
20.4  5.5 0.566
37.94  0.41 0.065
48
26/14/8 0.437
35.9  12.8 0.480
23/25 0.368
18.5  7.4 0.828
19.6  5.0 0.500
37.95  0.47 0.168
(nasal obstruction and rhinorrhoea), headache, fatigue, myalgia,
moderate, and 3 severe). Numerical variables are presented as
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Figure 5 The number of influenza-virus-positive patients in
influenza-confirmed population after three-day treatment.
*
*
*
Figure 3 Improved percentage in symptom scores after one-
day treatment in influenza-comfirmed patients. *P< 0.05,
Placebo vs. Antiwei. Improved percentage in symptom scores
defines that difference between the symptom score at baseline
and after one-day treatment is divided by the symptom score
at baseline.
Chinese herbs in treatment of influenza: A randomized, double-blind, placebo-controlled trial 1367early as 10 h after the start of treatment (Fig. 4). Antiwei
treatment resulted in 20% more patients becoming afebrile
within 24 h, as compared to placebo (PZ 0.011).
In the influenza-confirmed population, influenza virus
decreased to 27.2% in the Antiwei group and 58.7% in the
placebo group after three days of treatment (PZ 0.001)
(Fig. 5).
Compliance
Compliance with medication was high in both treatment
groups. The majority patients (nZ 446) recorded taking
more than 90% of medication.
Safety
Antiwei was generally well tolerated compared with
placebo, with no increase in withdrawal rates because of
adverse events. One patient given Antiwei reported mild
paroxysmal palpitation but this resolved within two days
and did not result in withdrawal from the study. Laboratory
results, ECG and vital signs did not differ significantly from
baseline between the two groups.
Discussion
Most of the patients included in this study came from an
epidemic region during the influenza season.18e23 After DFA
screening with nasopharyngeal swabs, the positive rate in0.00
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Figure 4 Time to alleviation of fever in influenza-confirmed
patients within the first 24 h after treatment. P< 0.05 Placebo
vs. Antiwei.our study was 48.2%, which is slightly lower than 61.0% in
Zambon’s study.24 The oral administration of 6 g of Antiwei
twice daily was associated with significant clinical and
antiviral effects in healthy adults with naturally occurring
influenza when given within 36 h of onset and was generally
well tolerated. For patients with influenza-like illness, the
number of recovered patients after three days of treatment
in the Antiwei group increased 17% and the severity of
symptoms was significantly reduced 50% compared to
placebo. After one-day treatment, Antiwei’s benefit for
reducing fever was apparent and the other two key symp-
toms (cough and expectoration) were significantly
improved by the end of treatment. At the same time,
Antiwei was well tolerated, with safety similar to placebo.
Since the introduction of TCM to the world, there have
been debates regarding a role for herbal medicines in the
therapy of illness such as influenza infections. According to
Treatise on Cold-induced Diseases (Shang Han Lun),
a variety of herbal formulas have been used to treat
patients with infectious diseases for over 1800 years.
Chinese medicine is widely accepted amongst Chinese
populations. The use of Chinese medicine in treating
pandemic and endemic diseases has long been described in
traditional medical books such as Shang Han Lun, and
Huangdi’s Canon of Medicine (HuangDi Nei Jing). The
prescriptions for infectious diseases were made based on
the clinical presentations, rather than laboratory-
confirmed pathogens, which were beyond their knowledge
at that time. Only a small fraction of the thousands of
medicinal plants used worldwide has been tested rigorously
in randomized, placebo-controlled trials. Yet randomized,
controlled trials are the best way to demonstrate the effi-
cacy of any medical, herbal or conventional therapy.25
Although herbs or herbal products, as part of complemen-
tary and alternative therapies, have been proposed, their
effectiveness in treating or preventing influenza has not
been established beyond reasonable doubt.11 The extract
of elderberry was used to treat the influenza in the past,26
and two studies have demonstrated a significant benefit of
herbal products in prophylaxis against viral infection.27,28
Herbal supplement users have also reported significant
improvement in influenza-like symptoms such as chills,
cough, fatigue, and headache and quality-of-life measures
such as mental health score,27 as they have in our study.
1368 L. Wang et al.A variety of Chinese herbs have been widely used as
antipyretic drugs for clearing accumulated heat in the
lungs, according to the theory of TCM. One recent study by
Kubo T. et al. showed that there is a more antipyretic
effect of Mao-to, a Japanese herbal medicine, for treat-
ment of type A influenza infection in children, in compar-
ison to Oseltamivir.29 The Japanese traditional herbal
medicine includes Mahuang, Guizhi, Kuxingren and Gancao,
which as components were included in Antiwei. In our
study, the antipyretic effect was apparent within 24 h of
Antiwei administration, when influenza symptoms are
generally most troublesome. Although we did not assess
economic effects, the indirect costs of influenza such as
workplace absenteeism and performance at work could be
improved according to the clinical benefits observed in the
influenza-confirmed population and in the population with
influenza-like illness.30
Studies in animal experiments and in vitro, have
confirmed that Antiwei can inhibit growth of a variety of
virus, including influenza A and B, respiratory syncytial
virus (RSV), adenovirus etc (data not shown). We now show
that Antiwei can significantly reduced the positive rate of
influenza virus after treatment. These findings are consis-
tent with results from studies of other antiviral drugs for
influenza and other self-limiting viral diseases, for which
increased therapeutic benefit is obtained when treatment
is started as early as possible after symptom onset.31
The duration of cough and expectoration was shorter
and the severity of the two symptoms was generally lower
in the Antiwei groups (data not shown). Influenza is trans-
mitted by virus-laden secretions. Cough and expectoration
could be the most distressing symptoms of influenza and
also contributes to the spread of infection. Patients who
received Antiwei had significantly lower positive rate of
virus on laryngopharynx swabs than those in the placebo
group. Such differences, together with improvement of
symptoms, including cough and expectoration, may help to
reduce transmission of the virus.
Antiwei was generally well tolerated, with almost no
adverse events reported. Only one patient given Antiwei
reported mild paroxysmal palpitation, which was resolved
within two days without additional treatment. This
symptom was not associated with discontinuation rates in
the Antiwei group compared to placebo. No other adverse
effects or abnormalities in laboratory test were associated
with Antiwei treatment. It must be noted that the Antiwei
contains Mahuang, which has been reported to have some
side effects (such as chest pain, hypertension, arrhythmia,
myocardial infarction, stroke, or death32) when served as
a dietary supplement for weight reduction and perfor-
mance enhancement, but the use of Mahuang in this study
was not associated with any significant adverse events. In
our prescription, 6 g of Antiwei equals to 23 g of crude
herbs, in which there is 2.5 g of Mahuang, so the daily dose
of Mahuang was only 5.0 g, which is a small dosage
compared with the conventional dose in other TCM
treatments.
We recognize that this study does have some potential
limitations. We did not include follow-up after treatment,
and the symptoms of influenza were observed for only 4
days, thus by the end of study many patients had not fully
recovered. Therefore, the duration of illness and the timeof alleviation could not be exactly evaluated. In addition,
the protocol specifically excluded individuals with medical
conditions which would place them in high-risk populations
that are often associated with more severe influenza.
In conclusion, our study clearly indicated that Antiwei
was an effective treatment of influenza-confirmed and
influenza-like illness in otherwise healthy adults, and
Antiwei can provide an alternative to conventional treat-
ment for influenza or influenza-like symptoms. Antiwei
might also be a potent medication for use in influenza
pandemics and in situations where a shortage of antiviral
agents and vaccines exists. Our findings provide a rationale
for continuing studies of this agent in the treatment of
influenza, and these should now include studies in children
and in high-risk populations. Further large-scale studies to
investigate the other antiviral effect of Antiwei, and
studies of its mechanism(s) are also now required.
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